Just Breathe: Advances in Lung Disease Research

1PM – 2PM | Zinner Breakout Room
The abstract image of human lungs in the form of lines of communication network.

About the Session

 

We all have a cough from time to time. But for some patients, the struggle to breathe goes far beyond a head cold or a sporadic asthma attack. Diseases like cystic fibrosis, bronchitis, severe asthma, lung cancer, interstitial lung disease (ILD), and a host of rare pulmonary conditions can impact a person’s quality of life and make the simplest of activities – think, blowing out candles on a birthday cake – impossible. In this session, pulmonary experts will discuss various aspects of Interstitial Lung Disease including how patient care for this condition has evolved in the past decade, the impact of personalized medicine on the choice of current therapies and how BWH is partnering with industry to accelerate drug discovery in this area.

Speakers


MODERATOR:

  • Frank S. David, MD, PhD
    Managing Director, Pharmagellan

 

PANELISTS:

  • Susan Limb, MD
    Senior Medical Director, US Medical Affairs, Genentech

 

  • Benjamin Raby, MD, MPH
    Associate Physician, Brigham and Women’s Hospital
    Associate Professor of Medicine, Harvard Medical School

 

  • Ivan O. Rosas, MD
    Associate Physician, Brigham and Women’s Hospital
    Assistant Professor of Medicine, Harvard Medical School

 

  • Lisa Henske, MD (session chair)
    Associate Physician, Brigham and Women’s Hospital
    Professor of Medicine, Harvard Medical School

 

GUEST:

  • Janice Petrella

frank

Frank S. David, MD, PhD
Managing Director, Pharmagellan

Dr. David is the founder & Managing Director of Pharmagellan, a Boston-area healthcare consulting firm that advises established & emerging biomedical companies, entrepreneurs, & investors on R&D & corporate strategy. He previously served as Director of Strategy in AstraZeneca’s Oncology Innovative Medicines unit & co-founded the Transactional Consulting practice at Leerink Partners, a healthcare investment bank. Besides leading Pharmagellan, Frank is an Innovation Strategist at the Brigham Research Institute, an active mentor in MassBio’s MassCONNECT program for healthcare entrepreneurs, a blogger at Forbes.com, & an active member of the bio-Twitter community (@Frank_S_David). Dr. David received his M.D. & Ph.D. degrees from Columbia University’s College of Physicians & Surgeons, trained in Anatomic Pathology at BWH, & served as Instructor in Pathology at BWH & Harvard Medical School.

limb

Susan Limb, MD
Senior Medical Director, US Medical Affairs, Genentech

Dr. Limb is a senior medical director in US Medical Affairs at Genentech. She is currently the US medical team leader for pirfenidone. Prior to joining Genentech in 2015, she served as a clinical team leader in the Division of Pulmonary, Allergy, & Rheumatology Products at the FDA. She earned her undergraduate degree in Biochemical Sciences at Harvard University in 1996 & her medical degree at Johns Hopkins University School of Medicine in 2000. She completed both residency & fellowship at Johns Hopkins Hospital & is currently board-certified in Internal Medicine & Allergy & Clinical Immunology.

henske

Lisa Henske, MD (session chair)
Associate Physician, Brigham and Women’s Hospital
Professor of Medicine, Harvard Medical School

Dr. Henske is best known for her groundbreaking discovery that mutations in the TSC2 gene cause the sporadic form of lymphangioleiomyomatosis (LAM).  This provided the foundation for pivotal clinical trials demonstrating the efficacy mammalian/mechanistic target of rapamycin (mTOR) inhibitors for the treatment of LAM.   Her laboratory has also discovered that autophagy plays a critical role in the pathogenesis and therapy of LAM, leading to an ongoing clinical trial called the “SAIL” trial: Sirolimus and Autophagy Inhibition in LAM.

In addition to her position at the Brigham and Women’s Hospital, Dr. Henske is a Professor of Medicine at Harvard Medical School, an Associate Member of The Broad Institute of MIT and Harvard, and a practicing medical oncologist at the Lank Center for Genitourinary Cancer at the Dana-Farber Cancer Institute. Dr. Henske earned her undergraduate degree summa cum laude from Yale University, where she majored in Molecular Biophysics and Biochemistry and was elected to Phi Beta Kappa. She earned her MD degree from Harvard Medical School. She completed her Residency in Internal Medicine and a Fellowship in Hematology/Oncology at the Massachusetts General Hospital in Boston, followed by Post-doctoral training in cancer genetics at the Brigham and Women’s Hospital. In 1996 she established her own laboratory at Fox Chase Cancer Center in Philadelphia PA, where she rose to the rank of Senior Member before returning to the Brigham and Women’s Hospital in 2008.

Dr. Henske is a member of the American Society of Clinical Investigation and the Association of American Physicians. She is an elected member of the Board of Directors of the Tuberous Sclerosis Alliance. She is active in the mentoring and teaching of Harvard Medical School students through the Health Sciences and Technology (HST) Program, and in the teaching of graduate students at Harvard Medical School.

raby

Benjamin Raby, MD, MPH
Associate Physician, Brigham and Women’s Hospital
Associate Professor of Medicine, Harvard Medical School

Dr. Raby is a pulmonologist and genetic epidemiologist with an interest in the genetics of lung disease and the Director of the BWH Pulmonary Genetics Center, a first-of-its kind clinical and research center that serves patients with suspected genetic pulmonary disorders. His research focuses primarily on identifying the molecular determinants of asthma in human populations. He has developed four NIH-funded studies that use genome-wide approaches. “Genetics and Gene Expression Profiling in Asthma” aims to identify asthma-associated regulatory genetic variants. He has developed gene expression signatures for asthma-associated traits and methods to facilitate expression quantitative trait locus mapping studies. These efforts resulted in identification of regulatory variants that influence the expression of 1,585 genes, including novel asthma susceptibility variants, and have developed a pipeline to functionally characterize the identified asthma genes. The second project, “The Asthma BioRepository for Integrative Genomics Research”, is a nation-wide effort to establish a publicly accessible repository of cell lines from 1,500 asthmatic and healthy subjects, accompanied by genome-wide genotype, gene expression and methylation profiles for all 1,500 subjects to facilitate integrative, systems-based approaches for the study of asthma and other traits. The third project, “Structural Genetic Variation in Asthma”, is supporting a genome-wide association study of copy number variation (CNVs) in asthma. The fourth, “Integrative Genomics of Acute Asthma Control” focuses on leveraging clinical, genomic and environmental data to understand the molecular determinants of suboptimal asthma control. Dr. Raby is also a founding member of the EVE Asthma Consortium, and collaborates on a variety of asthma and COPD projects.

 

rosas

Ivan O. Rosas, MD
Associate Physician, Brigham and Women’s Hospital
Assistant Professor of Medicine, Harvard Medical School

Dr. Ivan O. Rosas is a physician at Brigham and Women’s Hospital (BWH). He is also an assistant professor of medicine at Harvard Medical School.

After receiving his medical degree from the National University of Colombia, Dr. Rosas completed a residency in internal medicine at Jackson Memorial Hospital . He then participated in two fellowship programs: the first in pulmonary and critical care at Johns Hopkins University, and the second at the National Heart, Lung, and Blood Institute (NHLBI). He is board certified in critical care medicine, internal medicine and pulmonary disease.

Dr. Rosas’s clinical interests include autoimmune lung disease, interstitial lung disease, pulmonary fibrosis and sarcoidosis. His main clinical research activities have focused on the detection of pulmonary fibrosis and interstitial lung disease in populations at risk. His translational research investigates the proteins that are connected to the progression of pulmonary fibrosis. He has authored over 70 peer-reviewed publications, has received funding from the National Institutes of Health, and is a member of both the BWH Interstitial Lung Disease Clinic and the BWH Lung Transplant Program.